Brii Biosciences’ BRII-179 Vaccine on Track for Breakthrough Therapy Designation in China
China’s Center for Drug Evaluation (CDE) website has indicated that Brii Biosciences Ltd (HKG: 2137),...
Viral hepatitis
Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook
Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...
GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
Fujian Cosunter Gains Ethical Approval for Phase IIa Study of GST-HG131 in Hepatitis B
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of ethical approval...
Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C
China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...
Gilead Partners with Assembly Biosciences in $84.8 Million Collaboration for Antiviral Therapies
Gilead Sciences (NASDAQ: GILD) has announced a significant 12-year collaboration with antiviral specialist Assembly Biosciences...
Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B
China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...
YiChang HEC ChangJiang Pharmaceutical’s Yiqibuvir Receives NMPA Review for Hepatitis C Treatment
China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced that the National Medical...
Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies
China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...
Helio Genomics’ Sister Company LAMH Wins NMPA Approval for Liver Cancer Test in China
Helio Genomics has announced that its ‘sister company’ Laboratory for Advanced Medicine & Health Group...
WestGene Biopharma Secures $42 Million in Funding to Advance mRNA Therapeutics
Chengdu-based mRNA specialist WestGene Biopharma has reportedly raised USD 42 million via a funding round,...
Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023
China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...
Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023
China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...
Ascletis Pharma Inc. Ceases Promotion of Hepatitis C Products and Halts Development of ASC06 and ASC09
China-based Ascletis Pharma Inc., (HKG: 1672) has announced significant business adjustments, including the decision to...
TianLong Science and Technology Expands into Northern Thailand with Hepatitis Diagnostics
Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply...
NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment
Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...
Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments
Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...
China’s CDE Unveils Technical Guidelines for Stem Cell Products and Immunotherapy in Chronic Hepatitis B
The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines aimed at...
Priority Review Status Anticipated for HH-003, BI655130, VIS649, and Remternetug by CDE
The Center for Drug Evaluation (CDE) website has indicated that Huahui Health’s HH-003, Boehringer Ingelheim’s...
AusperBio Initiates Phase I Trial for AHB-137 in New Zealand
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...